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Factors affecting long-term survival after surgical 
resection of pancreatic ductal adenocarcinoma
Kyoung Won Yoon, Jin Seok Heo, Dong Wook Choi, Seoung Ho Choi
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Purpose: Some patients who undergo surgical resection of pancreatic cancer survive longer than other patients. The purpose 
of this study was to identify the factors that affect long-term survival after resection of histopathologically confirmed pancre-
atic ductal adenocarcinoma. Methods: A single-center, retrospective study was conducted among 164 patients who under-
went surgical resection of pancreatic cancer, between May 1995 and December 2004. The patient follow-up process was con-
ducted via telephone survey and review of electronic medical records for at least 5 years or until death. Results: We com-
pared patients with long-term (≥60 months, n = 19) and short-term survival (＜60 months, n = 145). Resection margin status, 
differentiation of the tumor, tumor stage, pre-operative serum level of albumin, total bilirubin and carbohydrate antigen 
(CA) 19-9 level are related with survival difference (all factors, P ＜  0.05). Multivariate analysis revealed that a pre-operative 
serum total bilirubin level ＜7 mg/dL and a pre-operative serum CA19-9 level ＜37 U/mL is a statistically significant prog-
nostic factor for long-term survival. Conclusion: The preoperative serum total bilirubin and serum CA19-9 levels are asso-
ciated with long-term survival after surgical resection of pancreatic cancer.
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INTRODUCTION
The 5-year survival rate of patients with pancreatic can-
cer in Korea was 8.0% between 2001 and 2005, 7.7% be-
tween 2003 and 2007 [1]. Although the death rates of most 
malignancies have declined, the poor prognosis of pancre-
atic cancer has not improved with advances in proper cu-
rative surgical resection [2,3]. 
Nevertheless, some patients who underwent surgical 
resection of pancreatic cancer survive longer than other 
patients [4]. It is important to predict the prognosis of pa-
tients with pancreatic cancer after surgical resection to 
provide proper surgical and adjuvant management, 
which may thus improve the survival of patients with pan-
creatic cancer [5,6].
In previous studies, clinical factors associated with sur-
vival after surgical resection have not been thoroughly 
studied. Some histopathologic findings of long-term sur-
vivors have been shown to resemble the findings of other 
kinds of neoplasm by the review of slides in a previous 
study. In other previous studies, follow-up period data 
have usually been ＜5 years because of the poor prognosis Survival factors of pancreatic cancer
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of pancreatic cancer [7,8]. 
The purpose of this study was to identify the clinical fac-
tors that affect long-term survival after resection of histo-
pathologically confirmed pancreatic ductal adenocarci-
noma.
METHODS
A retrospective study was conducted among 176 pa-
tients who underwent surgical resection of pancreatic can-
cer at Samsung Medical Center between May 1995 and 
December 2004. The demographic, clinical data and lab 
findings based on electronic medical records at this center 
were reviewed. The body mass index (BMI) data were 
based on the anesthesia records maintained during 
surgery. The serum levels of albumin, hemoglobin, total 
bilirubin, and carbohydrate antigen (CA) 19-9 were based 
on data from the day of admission. The slides of cancer 
specimen were re-evaluated by pathologists to confirm 
the diagnosis. Eleven patients were excluded because the 
final diagnoses were mucinous cystic neoplasms, intra-
ductal papillary mucinous neoplasms, squamous cell car-
cinomas, and leiomyosarcomas. One patient was lost to 
follow-up and excluded. One hundred sixty-four patients 
were thus enrolled.
Patient follow-up was conducted through telephone 
survey. The duration of the follow-up period was at least 
60 months or until the patient’s death. The records of death 
were based on data from the National Statistical Office of 
Korea. Patients who survived ≥60 months after surgical 
resection were considered long-term survivors.
All of the long-term survivors after surgical resection of 
pancreatic cancer who were included in this study were fi-
nally re-confirmed to have ductal adenocarcinoma of the 
pancreas by histopathologic review. The stage was classi-
fied according to the cancer staging system published by 
the American Joint Committee on Cancer, 7th edition.  
An independent t-test, Pearson’s chi-square test, line-
ar-by-linear association, and Fisher’s exact test were used 
to analyze the factors. P ＜  0.05 were considered statisti-
cally significant. The variables that had prognostic poten-
tial, as suggested by univariate analysis, were subjected to 
multivariate analysis with a logistic regression model [9]. 
All statistical analyses were performed using SPSS ver. 
18.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Nineteen of 164 patients (11.6%) of the patients ach-
ieved 60-month long-term survival after surgical resection 
of pancreatic cancer. Among the long-term survival 
group, 15 patients were alive on 1 January 2010. The mean 
duration of survival of the 145 patients in the short-term 
survival group was 483 ± 348.7 days (range, 21 to 1,632 
days) since the day of surgery. The mean age of all the pa-
tients (98 [59.8%] men and 66 [40.2%] women) included in 
this study was 59 ± 9.9 years (range, 32 to 80 years).
The majority of patients (92.7%) had one or more symp-
toms at the time of admission, including abdominal pain, 
jaundice, and dyspepsia. Ninety-one (55.5%) patients un-
derwent pre-operative intervention for biliary drainage or 
decompression because obstructive jaundice developed 
secondary to the tumor located in the head or body of 
pancreas. Seventy-six patients (46.3%) had an American 
Society of Anesthesiologists (ASA) score of 1 and 88 pa-
tients (53.6%) had an ASA Score ＞1.
The following surgical procedures were performed: 
Whipple procedure, 66 patients (39.0%); pylorus-preserv-
ing pancreaticoduodenectomy, 42 patients (25.6%); distal 
pancreatectomy, 30 patients (18.3%); and total pancrea-
tectomy, 26 patients (15.9%). The location of tumor in 130 
patients (79.2%) was the head or neck of pancreas, includ-
ing uncinate process of 2 patients; 23 patients (14.0%) was 
the body of pancreas; and 11 patients (6.7%) was the tail of 
pancreas. 
A transfusion of packed red blood cells (pRBCs) was re-
quired in 68 patients (41.5%) intra-operatively. Nine of the 
68 patients required massive transfusions, (＞10 units of 
pRBCs). The mean operative time was 340 ± 102 minutes 
(range, 110 to 700 minutes). In 126 patients (76.8%), includ-
ing all of the patients who achieved long-term survival, R0 
resections were performed. Negative margins could not 
be obtained (R1 and R2) in 38 patients (23.2%). Portal vein 
resections were performed in 3 patients in the long-term Kyoung Won Yoon, et al.
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Table 1. Demographic, clinical, and pathologic factors affecting 
survival after surgical resection of pancreatic cancer
Long-term 
survival 
(n = 19)
Short-term 
survival 
(n = 145)
P-value
Age (yr)  56.26 ± 9.03
a)  59.22 ± 10.03
a)   0.224
Gender
  Male
  Female
          12
            7
          86
          59
 0.748
d)
ASA Score
  1
  ＞1
          10
            9
          66
          79
 0.559
d)
BMI (kg/m
2)
  Normal BMI (＜25)
  Overweight/obese
          16
            3
        122
          23
 0.994
d)
Hospital days (day)  19.95 ± 8.52
a)  23.02 ± 19.66
a)  0.503
Albumin (g/dL)    4.06 ± 0.49
a)    3.80 ± 0.55
a)  0.050
Hemoglobin (g/dL)  12.90 ± 1.79
a)  12.63 ± 1.85
a)  0.563
CA 19-9 (U/mL)
  ＜37
  ≥37
          10
            9
          26
        119
 0.001
d)
Total bilirubin (mg/dL)
  ＜7
  ≥7
          18
            1
          82
          63
 0.010
c)
Preoperative intervention
  No intervention
  Intervention performed
          12
            7
          61
          84
 0.082
d)
Operation
  PPPD
  Whipple operation
  Total pancreatectomy
  Distal pancreatectomy
            7
            5
            3
            4
          35
          61
          23
          26
 0.535
d)
Operative time (min) 312.63 ± 101.75
a) 344.62 ± 101.70
a)  0.199
Resection of SMV or PV
  No resection 
  Resection performed
          16
            3
        126
          19
 0.723
c)
Transfusion
  No transfusion
  0 to 9 units
  ≥10 units
          13
            6
            0
          83
          53
            9
 0.236
b)
Resection status
  R0
  R1 or R2
          19
            0
        107
          38
 0.008
c)
Tumor location
  Head
  Body and tail
          14
            5
        116
          29
 0.523
d)
Differentiation
  Well 
  Moderate
  Poor
            5
          13
            1
          17
          99
          29
 0.033
b)
T stage
  T1
  T2
  T3
  T4
            1
            3
          15
            0
            1
            3
        130
          11
 0.010
b)
CA19-9, carbohydrate antigen 19-9.
Table 1. Continued
Long-term 
survival 
(n = 19)
Short-term 
survival 
(n = 145)
P-value
N stage
  N0
  N1
          11
            8
          66
          79
  0.309
d)
TNM Stage
  Ia
  Ib
  IIa
  IIb
  III
  IV
            1
            2
            8
            8
            0
            0
            1
            3
          58
          71
          11
            1
 0.021
b)
Adjuvant treatment
  No adjuvant treatment
  Treatment performed
            5
          14
          65
          80
 0.125
d)
PPPD, pylorus preserving pancreaticoduodenectomy; SMV, supe-
rior mesenteric vein; PV, portal vein; TNM, tumor, node, 
metastasis. 
a)Mean ± standard deviation. 
b)Linear-by-linear association. 
c)Fi-
sher’s exact test. 
d)Pearson’s chi-square test.
survival group and confirmed to be invasive pancreatic 
adenocarcinoma. In short-term survival group, 19 patients 
were required resection of the portal vein or superior mes-
enteric vein and 9 patients had confirmed invasive malig-
nancies.
The mean length of hospital day was 22 ± 18.7 days 
(range, 7 to 215 days), because some patients underwent 
adjuvant treatment subsequently after surgical treatment.
Ninety-four patients received post-operative adjuvant 
treatment; specifically, 69 patients (42.1%) received che-
motherapy and radiation therapy and 25 patients (15.2%) 
received chemotherapy alone. Whether or not adjuvant 
therapy was administered, recurrence of pancreatic cancer 
occurred in 99 patients (60.4%) after surgical resection.
All cases were confirmed to be ductal adenocarcinoma 
of the pancreas and classified with differentiation by histo-
pathologic review. The demographic, clinical, and patho-
logic factors of the long-term and short-term survival 
groups are listed in Table 1.
At the time of admission, the albumin level (P = 0.05), 
pre-operative serum total bilirubin level (3.14 ± 4.46 
mg/dL in the long-term survival group and 7.39 ± 7.97 
mg/dL in the short-term survival group, P = 0.01), pre-
operative serum CA19-9 level (194.74 ± 383.55 U/mL in the Survival factors of pancreatic cancer
thesurgery.or.kr 397
Table 2. Multivariate analysis of factors that show statistical 
significance of relationship with long-term survival after surgical 
resection of pancreatic cancer, based on the result of univariate 
analysis
Odds ratio
Confidence 
interval
P-value
Pre-operative serum  10.57 1.193-93.689 0.034
  total bilirubin (＜7 mg/dL)
Pre-operative serum 4.21 1.187-14.945 0.026
  CA19-9 (＜37 U/mL)
long-term survival group and 1,526.19 ± 3,756.46 U/mL in 
the short-term survival group, P ＜  0.01), resection status 
(P ＜  0.01), T stage (P = 0.01), and overall stage (P = 0.02) are 
factors affecting the survival of patient with surgically 
treated pancreatic cancer. Pre-operative total bilirubin lev-
el ＜3 mg/dL in 13 patients of long-term survival group 
and 66 patients in short-term survival group, and failed to 
show statistical significance for this level of total bilirubin 
(P = 0.06). Whereas age, gender, ASA score, BMI, length of 
hospital stay, hemoglobin concentration at the time of ad-
mission, pre-operative interventions, symptoms at the 
time of admission, operative time, intra-operative trans-
fusion of pRBCs, and adjuvant treatments did not corre-
late with long-term survival (all P ＞  0.05). 
The statistically significant variables (P ＜ 0.05) based 
on univariate analysis were included in a multivariate lo-
gistic regression model. Multivariate analysis identified a 
pre-operative serum total bilirubin ＜7 mg/dL and a 
pre-operative serum CA19-9 level ＜37 U/mL was a prog-
nostic factor for long-term survival (Table 2). Pre-oper-
ative serum total bilirubin ＜7 mg/dL and pre-operative 
serum CA19-9 level ＜37 U/mL were associated with bet-
ter survival outcome (Fig. 1). Mean overall survival was 30 
± 3.4 months (median 14 months). The mean survival in 
patients with pre-operative serum total bilirubin level ＜7 
mg/dL (100 of 164 patients) was 38.1 months (median 14.9 
months) compared with 16.6 months (median 11.4 mon-
ths) in those patients with pre-operative serum total bilir-
ubin level ≥7 mg/dL (64 of 164 patients, log-rank test P = 
0.002). The mean survival in patient with pre-operative se-
Fig. 1. Survival in 164 patients after surgical resection of 
pancreatic ductal adenocarcinoma. (A) Overall survival. (B) 
Survival dependent on preoperative serum total bilirubin level 
(＜7 mg/dL vs. ≥7 mg/dL; log-rank test, P ＝  0.002). (C) Survival 
dependent on preoperative serum carbohydrate antigen (CA) 
19-9 level (＜37 U/mL vs. ≥37 U/mL; log-rank test, P ＜  0.001).Kyoung Won Yoon, et al.
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rum CA19-9 level ＜37 U/mL (128 of 164 patients) was 46.6 
months (median 27 months) compared with 23 months 
(median 13 months) in those patient with pre-operative se-
rum CA19-9 level ≥37 U/mL (36 of 164 patients, log-rank 
test, P ＜  0.001).
DISCUSSION
Because pancreatic cancer is fatal, there are few 5-year 
survivors, even after surgical and adjuvant treatment, or 
using early detection by screening strategies. The factors 
affecting survival of pancreatic cancer have been studied 
by many investigators. 
Cleary et al. [10] conducted a study in patients with re-
sected pancreatic adenocarcinomas and reported that ear-
ly-stage disease is a prognostic factor for long-term 
survival. Cameron et al. [11] identified that the most im-
portant determinant of survival in patients with pancre-
atic cancer after surgical resection is the biologic proper-
ties of the tumor. Other studies have shown that age, 
symptoms, performance of a resection, tumor differen-
tiation, resection margin, BMI, adjuvant treatment, tumor 
markers, and other co-morbidities are prognostic factors 
[2,4-7,12-25]. Some of the studies were limited by few 
survivors. The differences in treatment, heterogeneous di-
agnosis of initial and secondary histopathologic review, 
and limited follow-up were also shortcomings of previous 
studies. Further investigation is still needed to identify 
factors related to long-term survival after surgical re-
section of pancreatic cancer.
Ouaissi et al. [24] reported increased mortality in pa-
tient ＞70 years of age. In the current study, age did not in-
fluence survival of patients with pancreatic cancer. Other 
factors, including gender, length of hospital stay, and ASA 
score had no statistical significance.
Michaud et al. [15] conducted studies and reported that 
obesity significantly increased the risk of pancreatic can-
cer and decreased survival in compared with a normal 
BMI. The mean BMI of the patients in the current study 
was 22.65 ± 2.83 kg/m
2; only 1 patient had a BMI ＞30 
kg/m
2. There was no statistically significant difference in 
BMI between the long-term and the short-term survival 
groups.
Smith et al. [26] suggested that the presence of jaundice 
at the time of resection had an adverse impact on early 
post-operative survival in pancreatic cancer patients un-
dergoing pre-operative biliary drainage. Ninety-one of 
the patients in the current study underwent pre-operative 
intervention for biliary drainage; however, this procedure 
did not affect long-term survival. Tumor-related biliary 
obstruction most often occurs when the tumor is located in 
the head or neck of the pancreas, rather than the body or 
tail. None of the patients who underwent distal pan-
createctomy received pre-operative intervention for bili-
ary drainage. Additionally, there was no significance in 
the tumor locations between the long-term and short-term 
survival groups. This finding might account for the differ-
ing results of our study and other studies.
There was no significant difference in the operative time 
between the long-term and short-term survival groups. 
Also, there was no significant transfusion-related decrease 
in survival. In other studies, performing surgery appears 
to be an important factor influencing survival [11]. 
Surgical margin status is thought to affect the survival 
of patients after surgical resection of pancreatic cancer 
[2,12,23]. We found that when R0 resection was not ach-
ieved, long-term survival was not guaranteed. Also, we 
found a statistically significant difference in surgical mar-
gin status after surgical resection between the long-term 
and short-term survival groups. 
Portal vein and/or superior mesenteric vein resections 
appear to decrease survival compared to cases in which 
vein resections are not performed [27]. Compared with 
R1/R2 resections, vein resections increase survival. Vein 
resections do not necessarily indicate a negative possi-
bility of long-term survival after surgical resection of pan-
creatic cancer, as previous studies have showed [6]. In the 
current study, 19 patients in the short-term survival group 
underwent vein resections; 9 of the 19 patients had in-
vasive pancreas adenocarcinoma, and 2 patients did not 
achieve R0 resection. It is not clear whether or not re-
section of cancer-invaded veins have a survival benefit. 
Because resection status was different in some cases, the 
analysis might have been biased.
There was statistical significance based on linear-by-lin-Survival factors of pancreatic cancer
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ear association in tumor differentiation and the survival 
group. In agreement with previous studies, histologic dif-
ferentiation could be a reliable factor affecting survival of 
pancreatic cancer [18].
We observed that cancer stage was associated with sur-
vival after surgical resection of pancreatic cancer. All pa-
tients who achieved long-term survival had early-stage 
disease (stages I and II) and the T stage was statistically 
significant, as reported in previous studies [10]. But in the 
current study, nodal status did not have a statistically sig-
n i f i c a n t  e f f e c t  o n  s u r v i v a l  o f  p a t i e n t  w i t h  p a n c r e a t i c  
cancer. According to other investigators, T stage and re-
gional lymph node spreading of cancer has been sug-
gested to be an important prognostic factor of survival in 
patients with pancreatic cancer [5,17,20]. In contrast, some 
investigators have suggested that patients with lymph 
node metastasis also have a chance for long-term survival 
[16]. Mukaiya et al. [28] suggested that the extent of lymph 
node dissection does not affect the prognosis of pancreatic 
cancer in advanced cases.
Like other studies [6,22,27], the effect of adjuvant treat-
ment showed no increase in survival in patient with pan-
creatic cancer in the current study. Furthermore, some of 
patients dropped out during adjuvant treatment because 
of intolerable side effects of the chemotherapy. These 
problems make further statistical evaluation difficult to 
progress. A number of other investigators [5,14,19,20,23,29] 
suggested that adjuvant treatment is effective for increas-
ing survival in patients with pancreatic cancer after surgi-
cal resection, and studies for proper regimen are ongoing.
We demonstrated that the pre-operative lab findings, 
with the exception of the hemoglobin level at the time of 
admission, had a statistically significant difference be-
tween the long-term and short-term survival groups. 
Efforts for developing the screening strategies discovered 
that the pre-operative serum CA19-9 level is related to sur-
vival after resection of pancreatic cancer. An elevated se-
rum bilirubin level and decreased serum albumin level 
pre-operatively had an unfavorable impact on prognosis 
[6,12,13,21,26]. The pre-operative serum levels of albumin, 
total bilirubin, and CA19-9 had a significant effect on 
survival. 
A multivariate logistic regression model identified a 
pre-operative serum total bilirubin ＜7 mg/dL and a 
pre-operative serum CA19-9 level ＜37 U/mL as statisti-
cally significant prognostic factors for long-term survival. 
Indeed, these factors were associated with long-term sur-
vival after surgical resection in patient with pancreatic 
cancer. Tempero et al. [30] examined that only three of 
whom were Lewis antigen A and B negative in twenty pa-
tients of study and none of these three patients had ele-
vated CA19-9 levels yet had detectable level of CA19-9 
(they were not 0, but 4, 10, and 14). Lack of Lewis antigen 
A and B does not mean complete lack the ability to secrete 
CA19-9. Due to the restriction of retrospective study, the 
data related to Lewis antigen A and B was unable to in-
clude additionally in this study. As result, careful inter-
pretations and additional investigations are needed.
The limitations of our study are as follow: First, co-mor-
bidities which may affect survival, such as diabetes, hy-
pertension, and chronic obstructive pulmonary disease, 
were not considered in the patients in the current study. 
Second, the regimen of adjuvant chemotherapy and dose 
of radiation therapy in this study was not specified, and 
some of patients dropped out during adjuvant treatment 
because of intolerable side effects of the chemotherapy or 
recurrence of cancer. Third, the causes of death of patients 
who had no radiologic evidence of recurrence were not 
clear. Disease-free survival was difficult to investigate in 
the current study. Fourth, we observed a patient with liver 
metastasis and a resection was performed during the sur-
gical procedure. The patient with pancreatic cancer and 
distant metastases were not included in the current study. 
Finally, there were no differences between the surgical sta-
pler and the hand-sewing method with respect to oper-
ative time, blood loss, and post-operative complications.
The pre-operative serum total bilirubin and pre-oper-
ative serum CA 19-9 levels were associated with long-term 
survival of patients with pancreatic cancer who under-
went surgical resection. The serum albumin level at the 
time of admission, resection status, tumor differentiation, 
and cancer stage also affected survival of patients with 
pancreatic cancer.Kyoung Won Yoon, et al.
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